Lantheus (NASDAQ:LNTH) Trading 5.1% Higher – Time to Buy?

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) traded up 5.1% during trading on Monday . The stock traded as high as $114.26 and last traded at $113.49. 195,166 shares changed hands during trading, a decline of 79% from the average session volume of 949,610 shares. The stock had previously closed at $107.98.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. Leerink Partners boosted their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Truist Financial lowered their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Finally, JMP Securities cut their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Lantheus Stock Performance

The firm has a market cap of $7.98 billion, a PE ratio of 18.85 and a beta of 0.51. The business has a 50 day simple moving average of $108.41 and a two-hundred day simple moving average of $95.60. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Insider Buying and Selling

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, President Paul Blanchfield sold 2,000 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lantheus

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock valued at $458,271,000 after purchasing an additional 389,828 shares during the last quarter. Farallon Capital Management LLC raised its stake in Lantheus by 53.7% in the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after buying an additional 796,000 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in Lantheus by 25.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock valued at $121,867,000 after buying an additional 394,837 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after acquiring an additional 19,071 shares in the last quarter. Finally, Swedbank AB grew its stake in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after acquiring an additional 125,843 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.